CN1152049C - 用生长激素促分泌素治疗胰岛素抗性 - Google Patents

用生长激素促分泌素治疗胰岛素抗性 Download PDF

Info

Publication number
CN1152049C
CN1152049C CNB988059231A CN98805923A CN1152049C CN 1152049 C CN1152049 C CN 1152049C CN B988059231 A CNB988059231 A CN B988059231A CN 98805923 A CN98805923 A CN 98805923A CN 1152049 C CN1152049 C CN 1152049C
Authority
CN
China
Prior art keywords
oxo
general formula
compound
ethyl
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB988059231A
Other languages
English (en)
Chinese (zh)
Other versions
CN1259140A (zh
Inventor
P��A����Ƥŵ
P·A·卡皮诺
�����桤����
C·国锋·赵
�����շ�������˹��
B·A·勒夫克
L·C·潘
J·L·特勒拉德瓦
M·P·萨威斯托斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of CN1259140A publication Critical patent/CN1259140A/zh
Application granted granted Critical
Publication of CN1152049C publication Critical patent/CN1152049C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
CNB988059231A 1997-06-25 1998-06-05 用生长激素促分泌素治疗胰岛素抗性 Expired - Fee Related CN1152049C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5079097P 1997-06-25 1997-06-25
US60/050,790 1997-06-25

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2004100334189A Division CN1530107A (zh) 1997-06-25 1998-06-05 用生长激素促分泌素治疗胰岛素抗性

Publications (2)

Publication Number Publication Date
CN1259140A CN1259140A (zh) 2000-07-05
CN1152049C true CN1152049C (zh) 2004-06-02

Family

ID=21967444

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB988059231A Expired - Fee Related CN1152049C (zh) 1997-06-25 1998-06-05 用生长激素促分泌素治疗胰岛素抗性
CNA2004100334189A Pending CN1530107A (zh) 1997-06-25 1998-06-05 用生长激素促分泌素治疗胰岛素抗性

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2004100334189A Pending CN1530107A (zh) 1997-06-25 1998-06-05 用生长激素促分泌素治疗胰岛素抗性

Country Status (40)

Country Link
US (3) US6448263B1 (Direct)
EP (1) EP1000085B1 (Direct)
JP (2) JP2000514099A (Direct)
KR (1) KR20010014224A (Direct)
CN (2) CN1152049C (Direct)
AP (1) AP1145A (Direct)
AR (1) AR012256A1 (Direct)
AT (1) ATE305477T1 (Direct)
AU (1) AU747510B2 (Direct)
BG (1) BG104008A (Direct)
BR (1) BR9810477A (Direct)
CA (1) CA2294464A1 (Direct)
CO (1) CO4950621A1 (Direct)
DE (1) DE69831745T2 (Direct)
DZ (1) DZ2539A1 (Direct)
EA (1) EA002089B1 (Direct)
EG (1) EG21712A (Direct)
ES (1) ES2248899T3 (Direct)
HN (1) HN1998000088A (Direct)
HR (1) HRP980361A2 (Direct)
HU (1) HUP0001922A3 (Direct)
ID (1) ID24345A (Direct)
IL (7) IL154116A0 (Direct)
IN (1) IN189724B (Direct)
IS (1) IS5275A (Direct)
MA (1) MA24581A1 (Direct)
NO (1) NO996205L (Direct)
NZ (1) NZ500655A (Direct)
OA (1) OA11242A (Direct)
PA (1) PA8452601A1 (Direct)
PE (1) PE105399A1 (Direct)
PL (1) PL337659A1 (Direct)
SK (1) SK175699A3 (Direct)
TN (1) TNSN98113A1 (Direct)
TR (1) TR199903257T2 (Direct)
TW (1) TW553943B (Direct)
UA (1) UA64751C2 (Direct)
WO (1) WO1998058949A1 (Direct)
YU (1) YU70199A (Direct)
ZA (1) ZA985546B (Direct)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105164129A (zh) * 2013-05-28 2015-12-16 拉夸里亚创药株式会社 多晶型物形式

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
US6541634B2 (en) * 1999-02-26 2003-04-01 Pfizer Inc. Process for preparing growth hormone secretagogues
US7721948B1 (en) * 1999-05-25 2010-05-25 Silverbrook Research Pty Ltd Method and system for online payments
EP1132388A3 (en) * 2000-03-09 2004-03-03 Pfizer Products Inc. Hexahydropyrazolo[4,3-c]pyridine metabolites
ES2333097T3 (es) 2000-05-31 2010-02-17 Raqualia Pharma Inc Uso de secretagogos de la hormona de crecimiento para estimular la motilidad gastrointestinal.
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
US20060128615A1 (en) * 2002-09-18 2006-06-15 Pierrette Gaudreau Ghrh analogues
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
BRPI0519728B1 (pt) * 2004-12-21 2016-12-13 Hercules Inc resinas catiônicas reativas e processo de fabricação de papel
US20070024388A1 (en) * 2005-07-27 2007-02-01 Hassan Tanbakuchi Slabline structure with rotationally offset ground
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
ES2604943T3 (es) 2007-02-09 2017-03-10 Ocera Therapeutics, Inc. Moduladores macrocíclicos del receptor de la grelina y procedimientos de uso de los mismos
US7862825B2 (en) * 2007-02-21 2011-01-04 Mladen Vranic Method of controlling tight blood glucose by somatostatin receptor antagonists
RU2403902C1 (ru) * 2009-06-15 2010-11-20 Илья Николаевич Медведев Способ снижения биологического возраста при нарушении толерантности к глюкозе
US8546416B2 (en) 2011-05-27 2013-10-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
KR20150003771A (ko) 2012-05-03 2015-01-09 노파르티스 아게 그렐린 수용체 효능제로서의 2,7-디아자-스피로[4.5]데스-7-일 유도체의 l-말레이트 염 및 그의 결정질 형태
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
MX377481B (es) * 2014-08-05 2025-03-07 Raqualia Pharma Inc Derivados de serina como agonistas del receptor de grelina.
WO2016067638A1 (en) * 2014-10-31 2016-05-06 Raqualia Pharma Inc. Tetrahydropyrazolopyridine derivatives as ghrelin receptor agonists
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
WO2024217441A1 (zh) * 2023-04-21 2024-10-24 长春金赛药业有限责任公司 GHSR 1a激动剂、药物组合物及其制备方法和应用
CN119285632A (zh) * 2024-10-09 2025-01-10 威海中腾医药科技有限公司 一种基于酵母醇脱氢酶催化氧化的卡普瑞林中间体的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3235550A (en) 1966-02-15 Anal g gesiaxoat t tail intravenous injection
US3190802A (en) 1961-10-09 1965-06-22 Boehringer Sohn Ingelheim Shaving composition and method of using same
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
GB2101114B (en) 1981-07-10 1985-05-22 Farmos Group Ltd Substituted imidazole derivatives and their preparation and use
US5242783A (en) 1991-07-31 1993-09-07 Eastman Kodak Company Photographic material and process
AU676525B2 (en) 1992-11-06 1997-03-13 Merck & Co., Inc. Substituted dipeptide analogs promote release of growth hormone
HUT72076A (en) 1992-12-11 1996-03-28 Merck & Co Inc Process for preparing spiro piperidines and homologs which promote release of growth hormone and pharmaceutical compositions containing them
US5492916A (en) * 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
WO1995013069A1 (en) 1993-11-09 1995-05-18 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
BR9610277A (pt) 1995-08-31 1999-07-06 Schering Corp Derivados de piperazino como antagonistas de neurowuinina
EP0766966A3 (en) * 1995-09-08 2001-02-28 Eli Lilly And Company Method of treating insulin resistance
PL327227A1 (en) 1995-12-22 1998-12-07 Novo Nordisk As Compounds exhibiting growth hormone liberating properties
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
ATE356139T1 (de) * 1997-06-25 2007-03-15 Pfizer Dipeptidderivate zur förderung der sekretion von wachstumshormon
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105164129A (zh) * 2013-05-28 2015-12-16 拉夸里亚创药株式会社 多晶型物形式
US9499543B2 (en) 2013-05-28 2016-11-22 Raqualia Pharma Inc. Polymorph forms
CN105164129B (zh) * 2013-05-28 2018-01-19 拉夸里亚创药株式会社 多晶型物形式

Also Published As

Publication number Publication date
IL154114A0 (en) 2003-07-31
IL154116A0 (en) 2003-07-31
IL156465A0 (en) 2004-01-04
HN1998000088A (es) 1999-01-08
ES2248899T3 (es) 2006-03-16
NO996205D0 (no) 1999-12-15
AP1145A (en) 2003-02-14
EP1000085B1 (en) 2005-09-28
JP2005097261A (ja) 2005-04-14
HUP0001922A2 (hu) 2000-12-28
IL154112A0 (en) 2003-07-31
EP1000085A1 (en) 2000-05-17
US6448263B1 (en) 2002-09-10
EA199901075A1 (ru) 2000-08-28
HK1028051A1 (en) 2001-02-02
PA8452601A1 (es) 2000-05-24
ZA985546B (en) 2000-01-10
HRP980361A2 (en) 1999-02-28
IL156465A (en) 2004-07-25
TR199903257T2 (xx) 2000-12-21
EA002089B1 (ru) 2001-12-24
CA2294464A1 (en) 1998-12-30
HUP0001922A3 (en) 2001-02-28
AP9801267A0 (en) 1998-06-30
IL133626A0 (en) 2001-04-30
UA64751C2 (uk) 2004-03-15
TNSN98113A1 (fr) 2005-03-15
PL337659A1 (en) 2000-08-28
YU70199A (sh) 2003-01-31
IL154115A0 (en) 2003-07-31
IN189724B (Direct) 2003-04-19
AU7445698A (en) 1999-01-04
NZ500655A (en) 2002-02-01
BR9810477A (pt) 2007-05-22
DE69831745D1 (de) 2006-02-09
DE69831745T2 (de) 2006-08-31
US6867202B1 (en) 2005-03-15
US20030100561A1 (en) 2003-05-29
CN1259140A (zh) 2000-07-05
WO1998058949A1 (en) 1998-12-30
TW553943B (en) 2003-09-21
BG104008A (en) 2000-07-31
JP2000514099A (ja) 2000-10-24
AR012256A1 (es) 2000-09-27
CN1530107A (zh) 2004-09-22
OA11242A (en) 2003-07-23
US6630487B2 (en) 2003-10-07
IL154111A0 (en) 2003-07-31
NO996205L (no) 1999-12-15
CO4950621A1 (es) 2000-09-01
DZ2539A1 (fr) 2003-02-08
MA24581A1 (fr) 1998-12-31
EG21712A (en) 2002-02-27
ATE305477T1 (de) 2005-10-15
KR20010014224A (ko) 2001-02-26
JP3742643B2 (ja) 2006-02-08
IS5275A (is) 1999-11-26
AU747510B2 (en) 2002-05-16
SK175699A3 (en) 2001-04-09
ID24345A (id) 2000-07-13
PE105399A1 (es) 1999-11-04

Similar Documents

Publication Publication Date Title
CN1152049C (zh) 用生长激素促分泌素治疗胰岛素抗性
CN1113895C (zh) 生长激素促分泌素
CN1045595C (zh) 合成3－氨基哌啶衍生物的中间体的制备方法
CN1036590C (zh) 新的巯基乙酰基酰胺衍生物的制备方法
CN1633297A (zh) 作为黑皮质素－4受体激动剂的酰化哌啶衍生物
CN1290847C (zh) 氮杂－芳基哌嗪类化合物
CN1688583A (zh) 用作治疗醛固酮介导的病症的药物的有机化合物
CN1232507C (zh) 生长激素促分泌剂
CN1842526A (zh) 苯并二氮杂䓬cgrp受体拮抗剂
CN1142911C (zh) 具有释放生长激素特性的化合物
CN1901908A (zh) 治疗性化合物及其用途
CN87101164A (zh) 次膦酸衍生物
CN1143647A (zh) 促进生长激素释放的二肽
CN1802369A (zh) Cgrp受体拮抗剂
CN1288464A (zh) 作为orl－1受体激动剂的4－(2－酮－1－苯并咪唑啉基)哌啶化合物
CN1617869A (zh) 作为尿压素ⅱ受体拮抗剂的4－(哌啶基－吡咯烷基－烷基－脲基)－喹啉类化合物
CN1812982A (zh) 苯并二氮杂䓬cgrp受体拮抗剂
CN1826116A (zh) 作为黑皮素－4受体激动剂的哌啶衍生物
CN1039323C (zh) 咪唑并吡啶衍生物的制备方法
CN1993363A (zh) 1,3－二取代的杂芳基nmda/nr2b拮抗剂
CN1097192A (zh) 逆转录酶病毒蛋白酶抑制剂
CN1950357A (zh) 用作tafia抑制剂的咪唑衍生物
CN1780820A (zh) 作为阿立新受体拮抗剂的喹喔啉－3－酮衍生物
CN1410059A (zh) 治疗方法和包含促生长激素分泌剂的药盒
CN1157224C (zh) 用作生长激素促分泌剂的新酰胺衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee